Drug intelligence / Profile preview

deoxypodophyllotoxin

Development stage
Unknown
Lead developer
Shenyang Pharmaceutical University
Modality
Small Molecules
01

Overview

Deoxypodophyllotoxin is a natural flavonolignan and a derivative of podophyllotoxin. It is classified as a small molecule tubulin inhibitor with potent antimitotic activity. Deoxypodophyllotoxin destabilizes microtubules by inhibiting tubulin polymerization and exhibits significant antitumor effects through cell cycle arrest and induction of apoptosis. It also inhibits angiogenesis and has demonstrated anti-inflammatory and antiviral properties. Mechanistically, it can inhibit the HIF-1α signaling pathway (reducing glycolysis in cancer cells), competitively bind to EGFR and MET kinases (suppressing their downstream signaling), induce reactive oxygen species (ROS) generation leading to endoplasmic reticulum stress and apoptosis via multi-caspase activation[3][4][6]. The compound is being developed primarily for oncology indications such as advanced malignant solid neoplasms[1]. Its originator organization is Shenyang Pharmaceutical University.

Other names
Anthricin(-)-Deoxypodophyllotoxin4-DeoxypodophyllotoxinIsoanthricinHernandionHernandin
02

Targets

EGFR T790M (Epidermal growth factor receptor T790M mutant)TUBB (Tubulin (alpha and beta subunits))MET (Mesenchymal-epithelial transition factor receptor)

Beyond the preview

Go deeper on deoxypodophyllotoxin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on deoxypodophyllotoxin.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call